26
|
Vo Chieu V, Wacker F, Rieder C, Schumann C, Ballhausen H, Ringe K. Evaluation of a semi-automatic segmentation software for assessment of ablation zone geometry and comparison of two different microwave ablation systems. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
27
|
Li X, Taratula O, Taratula O, Schumann C, Minko T. LHRH-Targeted Drug Delivery Systems for Cancer Therapy. Mini Rev Med Chem 2017; 17:258-267. [PMID: 27739358 PMCID: PMC6645782 DOI: 10.2174/1389557516666161013111155] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/1970] [Revised: 09/18/2016] [Accepted: 10/05/2016] [Indexed: 11/22/2022]
Abstract
Targeted delivery of therapeutic and diagnostic agents to cancer sites has significant potential to improve the therapeutic outcome of treatment while minimizing severe side effects. It is widely accepted that decoration of the drug delivery systems with targeting ligands that bind specifically to the receptors on the cancer cells is a promising strategy that may substantially enhance accumulation of anticancer agents in the tumors. Due to the transformed cellular nature, cancer cells exhibit a variety of overexpressed cell surface receptors for peptides, hormones, and essential nutrients, providing a significant number of target candidates for selective drug delivery. Among others, luteinizing hormonereleasing hormone (LHRH) receptors are overexpressed in the majority of cancers, while their expression in healthy tissues, apart from pituitary cells, is limited. The recent studies indicate that LHRH peptides can be employed to efficiently guide anticancer and imaging agents directly to cancerous cells, thereby increasing the amount of these substances in tumor tissue and preventing normal cells from unnecessary exposure. This manuscript provides an overview of the targeted drug delivery platforms that take advantage of the LHRH receptors overexpression by cancer cells.
Collapse
|
28
|
Roy Chowdhury M, Schumann C, Bhakta-Guha D, Guha G. Cancer nanotheranostics: Strategies, promises and impediments. Biomed Pharmacother 2016; 84:291-304. [DOI: 10.1016/j.biopha.2016.09.035] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 08/29/2016] [Accepted: 09/11/2016] [Indexed: 12/31/2022] Open
|
29
|
Duong T, Li X, Yang B, Schumann C, Albarqi HA, Taratula O, Taratula O. Phototheranostic nanoplatform based on a single cyanine dye for image-guided combinatorial phototherapy. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 13:955-963. [PMID: 27884637 DOI: 10.1016/j.nano.2016.11.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 10/28/2016] [Accepted: 11/17/2016] [Indexed: 01/26/2023]
Abstract
This study represents a novel phototheranostic nanoplatform based on the near-infrared (NIR) heptamethine cyanine dye, IR775, which is capable of concurrent real-time fluorescence imaging and cancer eradication with combinatorial phototherapy. To achieve water solubility and enhance tumor delivery, the hydrophobic IR775 dye was loaded into a biocompatible polymeric nanoparticle with a diameter of ~40nm and slightly negative surface charge (-2.34mV). The nanoparticle-encapsulated hydrophobic IR775 dye (IR775-NP) is characterized by an enhanced fluorescence quantum yield (16%) when compared to the water soluble analogs such as ICG (2.7%) and IR783 (8%). Furthermore, the developed IR-775-NP efficiently generates both heat and reactive oxygen species under NIR light irradiation, eradicating cancer cells in vitro. Finally, animal studies revealed that the IR775-NP accumulates in cancer tumors after systemic administration, efficiently delineates them with NIR fluorescence signal and completely eradicates chemo resistant cancer tissue after a single dose of combinatorial phototherapy.
Collapse
|
30
|
Reinmuth N, Gröschel A, Schumann C, Sebastian M, Wiewrodt R, Reck M. Therapieempfehlung für das metastasierte nicht-kleinzellige Lungenkarzinom. Pneumologie 2016; 70:567-78. [DOI: 10.1055/s-0042-113087] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Schumann C, Chan S, Khalimonchuk O, Khal S, Moskal V, Shah V, Alani AWG, Taratula O, Taratula O. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer. Mol Pharm 2016; 13:2070-83. [PMID: 27170529 DOI: 10.1021/acs.molpharmaceut.6b00205] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We report an efficient therapeutic modality for platinum resistant ovarian cancer based on siRNA-mediated suppression of a multifunctional DJ-1 protein that is responsible for the proliferation, growth, invasion, oxidative stress, and overall survival of various cancers. The developed therapeutic strategy can work alone or in concert with a low dose of the first line chemotherapeutic agent cisplatin, to elicit a maximal therapeutic response. To achieve an efficient DJ-1 knockdown, we constructed the polypropylenimine dendrimer-based nanoplatform targeted to LHRH receptors overexpressed on ovarian cancer cells. The quantitative PCR and Western immunoblotting analysis revealed that the delivered DJ-1 siRNA downregulated the expression of targeted mRNA and corresponding protein by more than 80% in various ovarian cancer cells. It was further demonstrated that siRNA-mediated DJ-1 suppression dramatically impaired proliferation, viability, and migration of the employed ovarian cancer cells. Finally, the combinatorial approach led to the most pronounced therapeutic response in all the studied cell lines, outperforming both siRNA-mediated DJ-1 knockdown and cisplatin treatment alone. It is noteworthy that the platinum-resistant cancer cells (A2780/CDDP) with the highest basal level of DJ-1 protein are most susceptible to the developed therapy and this susceptibility declines with decreasing basal levels of DJ-1. Finally, we interrogate the molecular underpinnings of the DJ-1 knockdown effects in the treatment of the ovarian cancer cells. By using various experimental techniques, it was revealed that DJ-1 depletion (1) decreases the activity of the Akt pathway, thereby reducing cellular proliferation and migration and increasing the antiproliferative effect of cisplatin on ovarian cancer cells; (2) enhances the activity of p53 tumor suppressor protein therefore restoring cell cycle arrest functionality and upregulating the Bax-caspase pathway, triggering cell death; and (3) weakens the cellular defense mechanisms against inherited oxidative stress thereby increasing toxic intracellular radicals and amplifying the reactive oxygen species created by the administration of cisplatin.
Collapse
|
32
|
Kaiser R, Schumann-Stoiber K, Schnitzer E, Füzesi L, Schumann C. Fataler aggressiver Verlauf einer pulmonalen lymphomatoiden Granulomatose infolge einer immunsuppressiven Therapie mit Azathioprin. Pneumologie 2016. [DOI: 10.1055/s-0036-1572202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Schumann-Stoiber K, Schmölz M, Wagner L, Miksch T, Dockhorn-Dworniczak B, Kaiser R, Schnitzer E, Schumann C. Pneumonektomie bei invasiv pulmonaler Aspergillose unter Steroiddauertherapie aufgrund fehlender Prophylaxe. Pneumologie 2016. [DOI: 10.1055/s-0036-1572104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Kaiser R, Schumann-Stoiber K, Rustler M, Schnitzer E, Schmölz M, Schumann C. Bridge to Endoxan-Rescue mit High-Flow Sauerstoff-Therapie bei prolongiertem schwerem hypoxämisch-respiratorischen Versagen bei Exazerbation einer pulmonalen Fibrose. Pneumologie 2016. [DOI: 10.1055/s-0036-1572203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Schumann-Stoiber K, Schmölz M, Rustler M, Kaiser R, Schnitzer E, Schumann C. Cuff-Leak Test zur Identifikation einer subglottischen Trachealstenose im prolongierten Weaning. Pneumologie 2016. [DOI: 10.1055/s-0036-1572099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Helck A, Schumann C, Aumann J, Thierfelder K, Strobl FF, Braunagel M, Niethammer M, Clevert DA, Hoffmann RT, Reiser M, Sandner T, Trumm C. Automatic path proposal computation for CT-guided percutaneous liver biopsy. Int J Comput Assist Radiol Surg 2016; 11:2199-2205. [DOI: 10.1007/s11548-015-1349-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2015] [Accepted: 12/30/2015] [Indexed: 10/22/2022]
|
37
|
Schuette W, Nieman B, Schneider C, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke M, Hoeffken G, Kortsik C, Reck M. 3077 65 plus: A randomized phase III trial of Pemetrexed and Bevacizumab vs. Pemetrexed, Bevacizumab and Carboplatin as 1st line treatment for elderly patients with advanced non-squamous, non-small cell lung cancer (NSCLC) - a subgroup analysis of age and gender. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31718-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Thatcher N, Ciuleanu TE, Ramlau R, Schumann C, Paz-Ares L, Depenbrock H, Nanda S, Chouaki N, Socinski M. Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Scheumann N, Gorges T, Penkalla N, Nowack B, Schalk T, Riethdorf S, Lücke K, Pantel K, Krahn T, Schumann C. Enumeration and Molecular Characterization of Circulating Tumor Cells in Lung Cancer Patients Using the Gilupi Cellcollector™, An Effective in Vivo Device for Capturing Ctcs. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv045.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Taratula O, Patel M, Schumann C, Naleway MA, Pang AJ, He H, Taratula O. Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. Int J Nanomedicine 2015; 10:2347-62. [PMID: 25848255 PMCID: PMC4378304 DOI: 10.2147/ijn.s81097] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
We report a novel cancer-targeted nanomedicine platform for imaging and prospect for future treatment of unresected ovarian cancer tumors by intraoperative multimodal phototherapy. To develop the required theranostic system, novel low-oxygen graphene nanosheets were chemically modified with polypropylenimine dendrimers loaded with phthalocyanine (Pc) as a photosensitizer. Such a molecular design prevents fluorescence quenching of the Pc by graphene nanosheets, providing the possibility of fluorescence imaging. Furthermore, the developed nanoplatform was conjugated with poly(ethylene glycol), to improve biocompatibility, and with luteinizing hormone-releasing hormone (LHRH) peptide, for tumor-targeted delivery. Notably, a low-power near-infrared (NIR) irradiation of single wavelength was used for both heat generation by the graphene nanosheets (photothermal therapy [PTT]) and for reactive oxygen species (ROS)-production by Pc (photodynamic therapy [PDT]). The combinatorial phototherapy resulted in an enhanced destruction of ovarian cancer cells, with a killing efficacy of 90%-95% at low Pc and low-oxygen graphene dosages, presumably conferring cytotoxicity to the synergistic effects of generated ROS and mild hyperthermia. An animal study confirmed that Pc loaded into the nanoplatform can be employed as a NIR fluorescence agent for imaging-guided drug delivery. Hence, the newly developed Pc-graphene nanoplatform has the significant potential as an effective NIR theranostic probe for imaging and combinatorial phototherapy.
Collapse
|
41
|
Taratula O, Schumann C, Duong T, Taylor KL, Taratula O. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy. NANOSCALE 2015; 7:3888-3902. [PMID: 25422147 DOI: 10.1039/c4nr06050d] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Multifunctional theranostic platforms capable of concurrent near-infrared (NIR) fluorescence imaging and phototherapies are strongly desired for cancer diagnosis and treatment. However, the integration of separate imaging and therapeutic components into nanocarriers results in complex theranostic systems with limited translational potential. A single agent-based theranostic nanoplatform, therefore, was developed for concurrent NIR fluorescence imaging and combinatorial phototherapy with dual photodynamic (PDT) and photothermal (PTT) therapeutic mechanisms. The transformation of a substituted silicon naphthalocyanine (SiNc) into a biocompatible nanoplatform (SiNc-NP) was achieved by SiNc encapsulation into the hydrophobic interior of a generation 5 polypropylenimine dendrimer following surface modification with polyethylene glycol. Encapsulation provides aqueous solubility to SiNc and preserves its NIR fluorescence, PDT and PTT properties. Moreover, an impressive photostability in the dendrimer-encapsulated SiNc has been detected. Under NIR irradiation (785 nm, 1.3 W cm(-2)), SiNc-NP manifested robust heat generation capability (ΔT = 40 °C) and efficiently produced reactive oxygen species essential for PTT and PDT, respectively, without releasing SiNc from the nanopaltform. By varying the laser power density from 0.3 W cm(-2) to 1.3 W cm(-2) the therapeutic mechanism of SiNc-NP could be switched from PDT to combinatorial PDT-PTT treatment. In vitro and in vivo studies confirmed that phototherapy mediated by SiNc can efficiently destroy chemotherapy resistant ovarian cancer cells. Remarkably, solid tumors treated with a single dose of SiNc-NP combined with NIR irradiation were completely eradicated without cancer recurrence. Finally, the efficiency of SiNc-NP as an NIR imaging agent was confirmed by recording the strong fluorescence signal in the tumor, which was not photobleached during the phototherapeutic procedure.
Collapse
|
42
|
Rososinska K, Langer F, Fähndrich S, Ballek D, Schumann C, Bals R, Lepper PM. Endoskopische Lungenvolumenreduktion als Teil einer multimodalen Therapie bei pulmonalem Adenokarzinom. Pneumologie 2015. [DOI: 10.1055/s-0035-1544659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Pawel JV, Tseng J, Dediu M, Schumann C, Moritz B, Mendell J, Jin X, Feng W, Copigneaux C, Beckman RA. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs). Pneumologie 2015. [DOI: 10.1055/s-0035-1544763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
Rüdiger S, Nasifoglu S, Beer A, Merk J, Kropf-Sanchen C, Gagiannis D, Schmidtke-Schrezenmeier G, Öfele H, Hübers B, Rottbauer W, Schumann C. Genauigkeit der PET/CT im thorakalen Staging des Lungenkarzinoms. Pneumologie 2015. [DOI: 10.1055/s-0035-1544733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Schumann-Stoiber K, Schmölz M, Kaiser R, Schumann C. Endoxan Rescue-Therapie unter ECMO bei steroidrefraktärer acute interstitial pneumonia. Pneumologie 2015. [DOI: 10.1055/s-0035-1544709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Schumann-Stoiber K, Schmölz M, Wagner L, Schumann C. Bridge to endoskopischer Lungenvolumenreduktion (ELVR) bei akuter Exazerbation der COPD (AECOPD) mittels ECCO2-R und NIV. Pneumologie 2015. [DOI: 10.1055/s-0035-1544705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
47
|
Wibmer T, Rudiger S, Kropf-Sanchen C, Stoiber KM, Rottbauer W, Schumann C. Relation of Exercise Capacity With Lung Volumes Before and After 6-Minute Walk Test in Subjects With COPD. Respir Care 2014; 59:1687-95. [DOI: 10.4187/respcare.03082] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
48
|
Socinski M, Paz-Ares L, Luft A, Szczesna A, Ciuleanu T, Szafranski W, Reck M, Balint B, Park K, Schumann C, Hirsch F, Depenbrock H, Nanda S, Chouaki N, Thatcher N. Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Reck M, Socinski M, Luft A, Szczesna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Brown J, Soldatenkova V, Chouaki N, Thatcher N. Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Dani RK, Schumann C, Taratula O, Taratula O. Temperature-tunable iron oxide nanoparticles for remote-controlled drug release. AAPS PharmSciTech 2014; 15:963-72. [PMID: 24821220 DOI: 10.1208/s12249-014-0131-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 04/10/2014] [Indexed: 01/09/2023] Open
Abstract
Herein, we report the successful development of a novel nanosystem capable of an efficient delivery and temperature-triggered drug release specifically aimed at cancer. The water-soluble 130.1 ± 0.2 nm iron oxide nanoparticles (IONPs) were obtained via synthesis of a monodispersed iron oxide core stabilized with tetramethylammonium hydroxide pentahydrate (TMAOH), followed by coating with the thermoresponsive copolymer poly-(NIPAM-stat-AAm)-block-PEI (PNAP). The PNAP layer on the surface of the IONP undergoes reversible temperature-dependent structural changes from a swollen to a collapsed state resulting in the controlled release of anticancer drugs loaded in the delivery vehicle. We demonstrated that the phase transition temperature of the prepared copolymer can be precisely tuned to the desired value in the range of 36°C-44°C by changing the monomers ratio during the preparation of the nanoparticles. Evidence of modification of the IONPs with the thermoresponsive copolymer is proven by ATR-FTIR and a quantitative analysis of the polymeric and iron oxide content obtained by thermogravimetric analysis. When loaded with doxorubicin (DOX), the IONPs-PNAP revealed a triggered drug release at a temperature that is a few degrees higher than the phase transition temperature of a copolymer. Furthermore, an in vitro study demonstrated an efficient internalization of the nanoparticles into the cancer cells and showed that the drug-free IONPs-PNAP were nontoxic toward the cells. In contrast, sufficient therapeutic effect was observed for the DOX-loaded nanosystem as a function of temperature. Thus, the developed temperature-tunable IONPs-based delivery system showed high potential for remotely triggered drug delivery and the eradication of cancer cells.
Collapse
|